PTJ
RYTM icon

Paul Tudor Jones’s Rhythm Pharmaceuticals RYTM Stock Holding History

Paul Tudor Jones’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Sell
13,886
-5,760
-29% -$521K ﹤0.01% 2128
2026
Q1 		$1.71M Buy
+19,646
New +$1.91M ﹤0.01% 1970
2025
Q3 		– Sell
-4,272
Closed -$270K – 3810
2025
Q2 		$270K Sell
4,272
-25,241
-86% -$1.55M ﹤0.01% 2949
2025
Q1 		$1.56M Buy
29,513
+14,268
+94% +$792K 0.01% 1507
2024
Q4 		$853K Buy
+15,245
New +$842K ﹤0.01% 1841
2024
Q2 		– Sell
-13,355
Closed -$579K – 2739
2024
Q1 		$579K Buy
13,355
+8,455
+173% +$370K ﹤0.01% 1583
2023
Q4 		$225K Sell
4,900
-24,444
-83% -$771K ﹤0.01% 2160
2023
Q3 		$673K Buy
29,344
+17,951
+158% +$402K 0.01% 1523
2023
Q2 		$188K Sell
11,393
-14,481
-56% -$261K ﹤0.01% 2241
2023
Q1 		$462K Buy
+25,874
New +$650K 0.01% 1660
2022
Q4 		– Sell
-83,796
Closed -$2.05M – 2786
2022
Q3 		$2.05M Sell
83,796
-41,620
-33% -$774K 0.04% 524
2022
Q2 		$520K Buy
125,416
+74,178
+145% +$406K 0.01% 1254
2022
Q1 		$590K Buy
51,238
+21,760
+74% +$191K 0.01% 1176
2021
Q4 		$294K Buy
+29,478
New +$331K ﹤0.01% 1857
2021
Q2 		– Sell
-66,852
Closed -$1.42M – 1897
2021
Q1 		$1.42M Buy
+66,852
New +$1.94M 0.03% 678
2018
Q3 		– Sell
-7,758
Closed -$243K – 1235
2018
Q2 		$243K Buy
+7,758
New +$212K 0.01% 876

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Paul Tudor Jones's RYTM Position: Q2 2026 in Review

Paul Tudor Jones reduced its Rhythm Pharmaceuticals (RYTM) stake by 29% in Q2 2026, selling an estimated $521K and leaving 13,886 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2128.

Paul Tudor Jones first reported a position in RYTM in Q2 2018 and has held it in 16 quarters since. The position peaked at $2.05M in Q3 2022. 300 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Paul Tudor Jones held 13,886 shares of Rhythm Pharmaceuticals worth $1.54M as of Q2 2026.
  • Paul Tudor Jones sold 5,760 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $521K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2128 holding.
  • Paul Tudor Jones first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 16 quarters since.
  • Paul Tudor Jones's Rhythm Pharmaceuticals position peaked at $2.05M in Q3 2022.
  • 300 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.